On November 11, CVS Health rose 3.03% in Regular Trading, trading at $87.875 per share, with turnover of $523 million.
The latest visible catalyst was a new analyst target-price revision: Argus lowered its price target to $105 from $114 while the stock continued to carry an average buy rating, with the mean analyst target around $110.38. That followed Barclays trimming its target to $107 from $108 days earlier, suggesting a more cautious valuation stance but not a broad downgrade in Street sentiment.
Recent fundamentals remain supportive. CVS Health reported third-quarter adjusted EPS of $2.09 on revenue of $108.399 billion, both above consensus, and guided to full-year adjusted EPS of at least $8.20 versus market expectations near $8.05. The company also said it plans to separate its retail pharmacy business from its insurance and pharmacy-benefit operations into two publicly traded companies in the first half of 2028, a move that has prompted investors to reassess valuation despite mixed initial market reaction.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments